These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 34876680)

  • 1. Revisiting fibrosis in inflammatory bowel disease: the gut thickens.
    D'Alessio S; Ungaro F; Noviello D; Lovisa S; Peyrin-Biroulet L; Danese S
    Nat Rev Gastroenterol Hepatol; 2022 Mar; 19(3):169-184. PubMed ID: 34876680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal fibrosis: ready to be reversed.
    Latella G; Rieder F
    Curr Opin Gastroenterol; 2017 Jul; 33(4):239-245. PubMed ID: 28402994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease.
    Qv L; Mao S; Li Y; Zhang J; Li L
    Front Cell Infect Microbiol; 2021; 11():755650. PubMed ID: 34900751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of antibiotics in the treatment of inflammatory bowel disease.
    Perencevich M; Burakoff R
    Inflamm Bowel Dis; 2006 Jul; 12(7):651-64. PubMed ID: 16804403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.
    Bamias G; Pizarro TT; Cominelli F
    Inflamm Bowel Dis; 2022 Mar; 28(3):337-349. PubMed ID: 34904152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory bowel disease-associated intestinal fibrosis.
    Park JM; Kim J; Lee YJ; Bae SU; Lee HW
    J Pathol Transl Med; 2023 Jan; 57(1):60-66. PubMed ID: 36623814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic modulation during intestinal fibrosis.
    Bos S; Laukens D
    J Dig Dis; 2020 Jun; 21(6):319-325. PubMed ID: 32406133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation.
    Scheibe K; Kersten C; Schmied A; Vieth M; Primbs T; Carlé B; Knieling F; Claussen J; Klimowicz AC; Zheng J; Baum P; Meyer S; Schürmann S; Friedrich O; Waldner MJ; Rath T; Wirtz S; Kollias G; Ekici AB; Atreya R; Raymond EL; Mbow ML; Neurath MF; Neufert C
    Gastroenterology; 2019 Mar; 156(4):1082-1097.e11. PubMed ID: 30452921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging pharmacotherapy for inflammatory bowel diseases.
    Luo H; Cao G; Luo C; Tan D; Vong CT; Xu Y; Wang S; Lu H; Wang Y; Jing W
    Pharmacol Res; 2022 Apr; 178():106146. PubMed ID: 35227890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Saccharomyces boulardii as a treatment option in IBD.
    Sivananthan K; Petersen AM
    Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
    Ahluwalia B; Moraes L; Magnusson MK; Öhman L
    Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A practical guide to chronic inflammatory bowel disease].
    Salvador Nunes L; Greuter T; Henchoz S; Schoepfer A
    Rev Med Suisse; 2021 Sep; 17(748):1448-1452. PubMed ID: 34468095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
    Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inflammatory bowel disease: an overview].
    Herrlinger K
    Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiology of IBD-Is It Still a Mystery?
    Kofla-Dłubacz A; Pytrus T; Akutko K; Sputa-Grzegrzółka P; Piotrowska A; Dzięgiel P
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
    Rieder F; Fiocchi C; Rogler G
    Gastroenterology; 2017 Feb; 152(2):340-350.e6. PubMed ID: 27720839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
    Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
    Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.